IRIS
TINARI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.809
EU - Europa 4.676
AS - Asia 2.489
SA - Sud America 245
AF - Africa 18
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 8
Totale 12.255
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.790
SG - Singapore 1.082
IT - Italia 982
IE - Irlanda 794
CN - Cina 765
UA - Ucraina 619
SE - Svezia 542
FR - Francia 427
GB - Regno Unito 395
DE - Germania 376
TR - Turchia 372
BR - Brasile 217
FI - Finlandia 175
IN - India 142
RU - Federazione Russa 117
BE - Belgio 59
VN - Vietnam 51
AT - Austria 47
CZ - Repubblica Ceca 41
NL - Olanda 39
HK - Hong Kong 32
CA - Canada 17
PL - Polonia 15
LT - Lituania 12
EU - Europa 9
AR - Argentina 8
AU - Australia 8
EG - Egitto 6
GR - Grecia 6
IQ - Iraq 6
IR - Iran 6
MA - Marocco 6
ES - Italia 5
IL - Israele 5
PT - Portogallo 5
CH - Svizzera 4
EC - Ecuador 4
JP - Giappone 4
PY - Paraguay 4
RO - Romania 4
TW - Taiwan 4
BD - Bangladesh 3
CO - Colombia 3
ID - Indonesia 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
CL - Cile 2
LU - Lussemburgo 2
NP - Nepal 2
UY - Uruguay 2
VE - Venezuela 2
AO - Angola 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
HR - Croazia 1
JO - Giordania 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
MX - Messico 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.255
Salva come PNG Salva come JPEG
Città #
Chandler 958
Dublin 780
Singapore 751
Jacksonville 738
Princeton 319
Southend 294
Nanjing 220
Izmir 212
The Dalles 188
Ann Arbor 178
Pescara 175
Ashburn 167
Chieti 155
Beijing 151
Santa Clara 150
Wilmington 144
Dearborn 134
Munich 127
Altamura 121
Boardman 118
Cambridge 109
Nanchang 71
Helsinki 66
New York 64
Los Angeles 62
Brussels 59
Woodbridge 58
Dong Ket 50
Vienna 40
Shenyang 34
Hebei 33
Rome 33
Brno 32
Ancona 31
Nuremberg 30
Hong Kong 29
Kunming 29
Norwalk 29
Tianjin 28
Jiaxing 26
Falls Church 24
Washington 22
Changsha 21
Milan 21
Houston 19
Amsterdam 18
Montesilvano 17
Frankfurt am Main 15
Hangzhou 15
São Paulo 15
Ascoli Piceno 14
Seattle 14
Düsseldorf 13
Grevenbroich 13
Kraków 13
Lanzhou 13
San Mateo 13
Changchun 11
Kocaeli 11
Pune 11
Giaveno 10
Guangzhou 10
Lappeenranta 10
Moscow 10
Corridonia 9
Auburn Hills 8
Bologna 8
Lanciano 8
Ottawa 8
Tappahannock 8
Augusta 7
Belo Horizonte 7
Campinas 7
Chicago 7
Leawood 7
London 7
Redwood City 7
San Vito Chietino 7
Ardabil 6
Cairo 6
Jinan 6
Menlo Park 6
Mumbai 6
Ningbo 6
Oklahoma City 6
Olomouc 6
Shanghai 6
Spoltore 6
Toronto 6
Vittuone 6
Andover 5
Bristol 5
Carini 5
Edinburgh 5
Madrid 5
Orange 5
Rio de Janeiro 5
Romola 5
Simi Valley 5
Zhengzhou 5
Totale 7.573
Salva come PNG Salva come JPEG
Nome #
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 226
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 139
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 125
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 117
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 115
New Targets for Therapy in Pancreatic Cancer 114
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 113
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 108
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 106
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 106
ERBB3 BINDING ANTIBODY 104
Occupational allergy: is there a role for nanoparticles? 104
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer 104
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 103
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 102
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 101
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 101
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 101
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 100
Allergooncology: an expanding research area 100
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 99
Prognostic relevance of LGALS3BP in human colorectal carcinoma 99
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 97
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 97
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 97
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 96
Exosomes as pleiotropic players in pancreatic cancer 96
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 95
DNA ploidy and S-phase fraction in pulmonary carcinoids. 94
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 94
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 94
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 94
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 92
Principali effetti collaterali delle terapie mediche 92
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 92
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 92
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 90
Novel inhibitors of pvhl-elongin c binding 90
An FPSE-HPLC-PDA method for the determination of anticancer drugs in human whole blood, plasma, and urine 90
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 89
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 89
Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion 89
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 88
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 87
Role of 90K protein in asthma and TH2-type cytokine expression. 87
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 87
Unknown primary tumors 86
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 86
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 86
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 84
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 83
Tumor-derived microvesicles: The metastasomes. 83
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 83
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 83
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 83
Prognostic value of 90K protein in HIV infection 82
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 82
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 82
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 82
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 82
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 81
CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy 80
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 80
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 80
A Flow cytometric study of early gastric cancer 80
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 80
Prognostic value of a novel circulating serum 90K antigen in breast cancer 79
A Stochastic Model for the HIV/AIDS Dynamic Evolution 79
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 79
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 79
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 79
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 79
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 79
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 78
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 77
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 77
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 77
A perspective analysis: microRNAs, glucose metabolism, and drug resistance in colon cancer stem cells 77
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 76
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 76
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 76
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 76
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 75
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 75
Combinations of biological response modifiers: rationale and clinical responses. 75
FPSE-HPLC-PDA METHOD FOR THE DETERMINATION OF INFLAMMATORY BOWEL DISEASE TREATMENT DRUGS IN WHOLE BLOOD, PLASMA AND URINE 75
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 74
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 74
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 74
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 74
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 72
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 72
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 72
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 72
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 71
Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer 70
null 70
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives 70
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 70
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 68
Totale 8.889
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.113
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.113
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020215 0 0 0 0 0 0 0 0 0 0 195 20
2020/20211.041 146 13 173 19 78 188 43 30 69 125 66 91
2021/2022891 35 22 15 174 78 37 35 69 59 22 94 251
2022/20232.683 216 341 202 307 267 483 147 236 300 22 103 59
2023/20241.415 121 46 79 63 85 457 236 54 41 40 15 178
2024/20252.921 178 606 501 105 87 184 344 237 357 216 106 0
Totale 12.930